Home › Topics › Ashwagandha
Adaptogens / Stress

Ashwagandha

One of the most clinically studied adaptogen supplements — with genuine RCT evidence for cortisol reduction, sleep quality, and testosterone in specific populations — and a growing safety controversy including liver toxicity case reports, nearly complete funder capture of the research literature, and a poorly understood thyroid stimulation signal
Patient Voice

"I took ashwagandha for about four months and the stress reduction was real — I felt genuinely less reactive, slept better, handled work pressure without that cortisol-spike feeling. Then around month three I started feeling emotionally flat. Not sad. Just... muted. I stopped and felt normal again within a week. I still recommend it to people but I tell them to use it in cycles."

— r/Supplements community member, 2024
Share this investigation 𝐱 Twitter/X Facebook LinkedIn Email
Share X FB in Email
Overview

Ashwagandha (Withania somnifera) is a root extract from Ayurvedic medicine with one of the largest bodies of randomized controlled trial evidence among adaptogen supplements. The compound is sold in multiple branded extract forms — most prominently KSM-66 (standardized to 5% withanolides from root-only extract) and Sensoril (standardized to 10% withanolides from root and leaf) — with meaningfully different pharmacological profiles, evidence bases, and safety signals. Human RCTs have demonstrated statistically significant reductions in cortisol and stress scores, improvements in sleep latency and quality, testosterone and DHEA-S elevations in specific male populations, and strength improvements in resistance-trained men. By the standards of the adaptogen category, this is a relatively substantial clinical evidence base. The complications begin when you examine who funded the research — the vast majority of positive RCTs were sponsored by Ixoreal Biomed, the manufacturer of KSM-66 — making independent replication rare and industry-independent effect estimation difficult. The adaptogen also carries a thyroid stimulation signal documented in a small RCT of subclinical hypothyroid patients, creating a potentially serious contraindication for people with hyperthyroidism or autoimmune thyroid conditions. And liver toxicity case reports — most notably a 2024 case series from Iceland — have prompted a formal USP herb safety review, adding a hepatotoxicity concern that was absent from the conversation even three years ago.

Key Findings
The Studies
not definitively established at the receptor level in humans.
The Anecdata
what does "working" actually feel like, and when?
The Uncertainty
"Cortisol reduction for everyone."
The Studies The Anecdata The Uncertainty
The Studies

Ashwagandha Clinical Evidence: Chandrasekhar 2012 Cortisol RCT (n=64, 27.9% Reduction in Context), Lopresti 2019 Independently-Funded Testosterone RCT (n=60, Overweight Men 40-70), Wankhede 2015 Resistance-Trained Strength Study (n=57), Ixoreal Biomed and Natreon Funder-Capture, KSM-66 vs Sensoril Standardization Divide, and the Population Specificity Boundary That Stressed Adults Are Not All Adults

Ashwagandha clinical evidence synthesized across the two proprietary-extract programmes (KSM-66 and Sensoril). Chandrasekhar 2012 (n=64, 60 days, KSM-66 300mg BID) found a 27.9% cortisol reduction and 44% Perceived Stress Scale improvement in chronically stressed adults — the flagship claim of ashwagandha marketing, funded by Ixoreal Biomed with no independent replication. Lopresti 2019 (n=60, 8 weeks, KSM-66 600mg/day) is the load-bearing trial: independently funded by an Australian health foundation, it found testosterone increases of 15% versus 2.6% placebo in overweight men aged 40-70 with mild fatigue — not clinically hypogonadal, but a real population boundary. Wankhede 2015 (n=57, 8 weeks) supports a parallel testosterone and strength signal in resistance-trained men, though Ixoreal-funded. Caveats: nearly every positive RCT is funded by the extract's manufacturer (Ixoreal for KSM-66, Natreon for Sensoril); no independently funded cortisol-reduction replication exists; population specificity = chronically stressed or overweight middle-aged men, not all adults; only standardized KSM-66/Sensoril at trial doses have documented withanolide content.
⏱ 5 min read
In This Section
  1. Mechanism of Action — HPA-Axis Modulation and a Secondary GABAergic Pathway, Both Incompletely Characterized
  2. Ixoreal Biomed and Natreon — the Ashwagandha Funding Structure
  3. Chandrasekhar 2012 (n=64) — the Headline Cortisol RCT in Context
  4. Lopresti 2019 (n=60) — the Load-Bearing, Independently-Funded RCT
  5. Wankhede 2015 (n=57) — the Parallel Strength-and-Testosterone Programme
  6. Dosage and Standardization — What 300 mg Twice Daily of KSM-66 Actually Means
  7. What the Research Honestly Supports — and What We'd Still Recommend

Mechanism of Action — HPA-Axis Modulation and a Secondary GABAergic Pathway, Both Incompletely Characterized

Two mechanisms have been proposed, both biologically plausible but not definitively established at the receptor level in humans. The primary proposal is modulation of the hypothalamic-pituitary-adrenal (HPA) axis: ashwagandha appears to blunt cortisol secretion and normalize glucocorticoid receptor sensitivity, the mechanism behind its stress-reduction reputation. The secondary is GABAergic activity — a non-withanolide component of ashwagandha root has shown sedative effects via GABA-A receptor modulation in rodent studies, the proposed basis for its sleep effects. Neither mechanism has been confirmed by direct cortisol or GABA receptor occupancy measurement in adequately powered independent human trials.

Ixoreal Biomed and Natreon — the Ashwagandha Funding Structure

Virtually all human clinical evidence comes from two proprietary standardized extracts. KSM-66 is produced by Ixoreal Biomed (root-only extract, standardized to a minimum 5% withanolides); Sensoril is produced by Natreon Inc. (root-and-leaf extract, standardized to 10% withanolides, 32% oligosaccharides). The structural fact this section names: every positive RCT for ashwagandha to date has been funded by the manufacturer of the extract being studied — Chandrasekhar 2012, Wankhede 2015, and Langade 2019 were all Ixoreal-funded. Every trial design decision — population, endpoint, dose, duration, statistical analysis — was made or approved by a party with direct financial interest in positive outcomes. No independently funded replication of the flagship cortisol finding exists.

Chandrasekhar 2012 (n=64) — the Headline Cortisol RCT in Context

Chandrasekhar et al. [1], published in the Indian Journal of Psychological Medicine, is the most-cited RCT. Sixty-four adults with a history of chronic stress were randomized to KSM-66 300mg twice daily or placebo for 60 days. Findings: a 27.9% reduction in serum cortisol versus 7.9% for placebo, and a 44% improvement in Perceived Stress Scale scores versus 5.5% for placebo. The 27.9% number is consistently misframed in marketing. Three reframings: (1) the sample was self-selected high-stress volunteers, not a clinical population, so the baseline cortisol elevation may have been unusually large; (2) the self-reported stress scale is the more subjective of the two primary outcomes and improved by a similar magnitude, suggesting shared measurement variance rather than two fully independent effects; (3) the trial was funded by Ixoreal Biomed, and no independent group has replicated a cortisol reduction of this size.

Lopresti 2019 (n=60) — the Load-Bearing, Independently-Funded RCT

Lopresti et al. [2], published in the American Journal of Men's Health, is the most rigorous ashwagandha trial for the population-specificity question — and the only positive RCT independently funded, by an Australian health promotion foundation rather than Ixoreal or Natreon. Sixty overweight men aged 40-70 with mild fatigue, but not clinically hypogonadal, were randomized to KSM-66 600mg/day or placebo for 8 weeks. Result: serum testosterone rose 15% versus 2.6% for placebo, and DHEA-S rose 18.1% versus 1.6%. Funded independently, this is the single most credible androgenic signal in the literature. The population-specificity boundary is the principal finding: Lopresti 2019 enrolled overweight, fatigued, middle-aged-to-older men and found a modest normalization; it does not predict effects in younger men, in men with normal baseline testosterone and no fatigue, or in women for hormonal endpoints.

Wankhede 2015 (n=57) — the Parallel Strength-and-Testosterone Programme

A parallel programme was conducted by Wankhede and colleagues, funded by Ixoreal Biomed. The most-cited paper, Wankhede et al. [3] in the Journal of the International Society of Sports Nutrition, randomized 57 resistance-trained men to KSM-66 300mg twice daily or placebo for 8 weeks alongside a standardized lifting program. Testosterone rose 96.2 ng/dL versus 18.0 ng/dL for placebo, and bench-press strength gains were significantly larger in the supplemented group. This is the one trial suggesting a strength-training-specific benefit, but the same funding caveat applies as to every KSM-66 trial: Ixoreal-funded, no independently funded replication in a resistance-training population exists.

Dosage and Standardization — What 300 mg Twice Daily of KSM-66 Actually Means

Clinical trial dose is 120-600 mg/day of KSM-66 or Sensoril for 6-8 weeks, delivering a minimum of 5% withanolides at KSM-66's standardization (Sensoril is standardized higher, to 10%, but includes leaf tissue and withaferin A, a compound with a distinct and less-established safety profile). A generic 500 mg "ashwagandha root extract" capsule can be labeled with either standardization or none at all, and analytical surveys of the retail market have found withanolide content well below label claims in a meaningful fraction of tested products. The "KSM-66" or "Sensoril" branding on a label is the most reliable available signal of standardization; unbranded "ashwagandha extract" conveys little about actual withanolide content delivered per dose.

What the Research Honestly Supports — and What We'd Still Recommend

The research supports a narrow but real conclusion: standardized KSM-66 at trial dose and duration appears to reduce cortisol and perceived stress in chronically stressed adults; it appears to modestly raise testosterone in overweight, fatigued, middle-aged-to-older men and in resistance-trained younger men; the proposed HPA-axis and GABAergic mechanisms are biologically plausible; short-term use (6-8 weeks) appears generally safe, with growing caveats around thyroid stimulation and rare hepatotoxicity covered in the uncertainty lens. What the research does not support: cortisol reduction of this magnitude replicated independently; testosterone elevation in men with normal baseline and no fatigue; effects beyond 8-12 weeks; effects of unbranded, unstandardized extract at consumer doses.

Ashwagandha is worth a 6-8 week trial of KSM-66 at 300-600 mg/day if you have elevated perceived stress, or are an overweight, fatigued, middle-aged man, and have not responded elsewhere. Expect first signal by week 2-3, plateau by week 6, steady state by week 8. Cleanest validation is a pre/post cortisol or testosterone panel at week 0 and week 8 on the standardized extract only. The population specificity boundary is the most important fact about this evidence base: the load-bearing trials enrolled chronically stressed or overweight middle-aged men, and the marketing that applies their findings to all adults is making a claim the data does not support. See also: the patient-experience lens for weeks 1/4/8 lived-evidence; the uncertainty lens for the funding-capture and standardization gaps.

Sources & References
  1. 2012
  2. 2019
  3. 2015
See also Low-Dose Naltrexone (LDN) — Naltrexone is FDA-approved at 50mg for opioid and alcohol use disorders. Low-dose naltrexone uses 1.5-4.5mg — one-tenth the dose — for autoimmune disease, fibromyalgia, and multiple sclerosis. Small RCTs show genuine benefit. The mechanism is plausible. The trials will likely never be funded, because naltrexone is generic.
The Anecdata

Ashwagandha Patient Experience: What KSM-66 Actually Feels Like Across Weeks 1, 4, and 8 for Stress, Sleep, and Testosterone — Reader Emails, r/Supplements and r/Nootropics Threads, and the Sleep-First / Stress-Gradual / Testosterone-Population-Bound Pattern That the Clinical Trials Did Track

Reader emails and r/Supplements / r/Nootropics threads mapped onto a weeks 1/4/8 timeline across three signals: stress and cortisol, sleep, and testosterone (in the resistance-trained or overweight and fatigued populations the trials enrolled). Sleep is the fastest-reported signal, often within the first several nights and well ahead of the 6-week Langade 2019 measurement window. Stress reduction accrues gradually and plateaus by Week 4, consistent with the Chandrasekhar 2012 60-day endpoint. Testosterone effects cluster almost exclusively in resistance-trained or overweight and fatigued readers — matching Wankhede 2015 (n=57) and the independently-funded Lopresti 2019 (n=60, overweight men 40-70). Caveat: a Week 8+ minority reports emotional blunting with no RCT correlate; cycling is community convention.
⏱ 4 min read
In This Section
  1. What "It's Working" Actually Feels Like Across the First Two Months
  2. Week 1 — Stress and Cortisol: Subtle, Not Dramatic
  3. Week 1 — Sleep: The Fastest-Reported Signal
  4. Week 1 — Testosterone: Not Yet Measurable
  5. Week 4 — Stress and Cortisol: The Plateau Begins
  6. Week 4 — Sleep: A Responder / Non-Responder Split
  7. Week 4 — Testosterone: The Responder Split Emerges
  8. Week 8 — The Emotional Blunting Caveat
  9. What This Means If You're Starting Ashwagandha

What "It's Working" Actually Feels Like Across the First Two Months

The most consistent reader question about ashwagandha is the practical one: what does "working" actually feel like, and when? The mechanistic answer — Chandrasekhar's cortisol RCT and the Lopresti/Wankhede testosterone data — lives in the clinical-evidence article on this page. This piece covers what the RCT cannot show: reader emails and r/Supplements / r/Nootropics threads mapped onto a weeks 1/4/8 timeline anchored on three signals — stress and cortisol, sleep, and testosterone (for the subset of readers where it plausibly applies).

Week 1 — Stress and Cortisol: Subtle, Not Dramatic

Week 1 stress reports are subtle rather than dramatic. Chandrasekhar 2012's 27.9% cortisol reduction was measured at day 60, not day 7; readers on KSM-66 300mg BID describe a gradual "edge coming off" rather than a sudden shift. A 2023 r/Supplements thread: "Week 1 I didn't notice anything specific — just, by day 5 or 6, I wasn't snapping at my kids as much." For low-baseline-stress readers, Week 1 reads as close to nothing.

Week 1 — Sleep: The Fastest-Reported Signal

Sleep is the fastest-reported signal — within the first several nights, well before any cortisol or hormonal endpoint is expected. Langade 2019 measured sleep onset latency at 6 weeks, but reader reports cluster much earlier. A late-2023 email: "Felt the sleep effect by night three." The GABAergic mechanism has been proposed, but the timing has not been confirmed in any human dose-response study.

Week 1 — Testosterone: Not Yet Measurable

For readers using ashwagandha with a testosterone goal, Week 1 is universally reported as undetectable. Both Wankhede 2015 and Lopresti 2019 measured testosterone at 8 weeks, not 1; no reader report claims a Week 1 hormonal shift, and several explicitly call it "obviously too early to feel anything hormonal" by day 7.

Week 4 — Stress and Cortisol: The Plateau Begins

By week 4, the stress-reduction signal has usually plateaued for continuous users. A 2022 r/Supplements thread: "By week 4 it's just baseline — I just am, I don't think about being 'less stressed.'" This tracks loosely with the Chandrasekhar 60-day timeline, where cortisol accrues across the full window rather than resolving early. Cleanest Week 4 read: the effect either has landed or it will not.

Week 4 — Sleep: A Responder / Non-Responder Split

Sleep reports at week 4 split clearly. A majority of readers maintain the Week 1 improvement — described as simply "the new normal." A smaller group reports the effect has faded, with pre-supplementation latency returning or a higher dose needed. The latter is unstudied: no RCT has tracked ashwagandha's sleep effect for tolerance beyond Langade's 6-week window, so the community's response remains empirical.

Week 4 — Testosterone: The Responder Split Emerges

By week 4, testosterone-focused readers report the first split. Resistance-trained readers on a structured lifting program — matching the Wankhede 2015 population — more often report subjective strength or recovery improvements; readers without a training program report no change. The Lopresti cohort (overweight men 40-70) maps onto a separate responder subgroup that reads more clearly at week 8. A 2023 r/Nootropics thread: "Lifting 4x/week, KSM-66 600mg — recovery is genuinely different by week 4, but I started tracking it then."

Week 8 — The Emotional Blunting Caveat

A smaller but consistent minority of Week 8+ reports describe an affective flattening — reduced emotional reactivity that goes beyond "calm" into what readers describe as "muted" or "flat." It has no RCT measurement, no confirmed mechanism, and no clinical guideline. The community's working response has been an 8-weeks-on / 2-weeks-off cycling convention, adopted empirically rather than from any clinical validation. Practical advice from long-term users on their first trial: stop, wait two weeks, reassess before concluding the effect is supplement-related.

What This Means If You're Starting Ashwagandha

The lived-experience pattern across roughly two hundred reader reports and recurring r/Supplements threads is consistent with the RCT literature's shape, if not its exact numbers: sleep is the fastest and most reliably reported signal; stress reduction accrues gradually across weeks 4-8; testosterone effects — where reported at all — cluster in readers who are chronically stressed, overweight and fatigued, or resistance-training, matching the populations Lopresti 2019 and Wankhede 2015 enrolled. The responder split reads most clearly at week 4 on stress, week 8 on testosterone; a baseline outside the trial populations is the most likely explanation for a Week 8 null.

See also: the clinical-evidence lens for the Chandrasekhar cortisol RCT, the Lopresti 2019 testosterone trial, and the Ixoreal / Natreon funder-capture structure; and the uncertainty lens for the emotional-blunting and standardization gaps and the absent long-term safety data.

See also Magnesium Threonate (Magtein) — A single human RCT with 44 participants is the entire clinical evidence base for a $500 million supplement market — and the patent holder funds most of the research
The Uncertainty

Ashwagandha Uncertainty: Which Marketing Claims Have the Weakest Evidence — Universal Cortisol-Reduction Extrapolation from Chandrasekhar 2012 Chronically-Stressed Cohort, HPA and GABAergic Mechanism Without Human Receptor-Level Confirmation, the Week 8 Emotional-Blunting Anecdote Promoted to RCT Grade, the 8-to-12-Week Trial-Duration Ceiling Outrunning "Long-Term Safe" Claims, and Five Label Red Flags That Distinguish Trial-Grade KSM-66 / Sensoril from Generic Root Powder

Ashwagandha marketing rests on four claims weaker than the published evidence supports. Universal "cortisol reduction for everyone" extrapolates the Chandrasekhar 2012 chronically-stressed-cohort result (n=64, KSM-66 300mg BID, 60 days, 27.9% mean cortisol reduction vs 7.9% placebo) to adults with low-normal baseline cortisol — the data does not transfer. HPA-axis and GABA-A mechanism claims are plausible but unconfirmed by receptor-level measurement. "Non-sedative calm" framing elides the Week 8+ emotional-blunting community signal and the empirical 8-weeks-on / 2-weeks-off cycling convention that emerged from it. "Safe to take long-term" outruns the 8–12 week trial-duration ceiling, sparse hepatotoxicity case-report literature, and documented thyroid-axis effects (TSH / T3 / T4 upregulation; contraindicated in hyperthyroid patients). Retail labels fail verification: withanolide standardization varies from ≥5% in KSM-66 (root-only, Ixoreal) to ~10% in Sensoril (root+leaf including withaferin A, Natreon); most SKUs disclose mg-per-serving but no withanolide %; Ixoreal and Natreon serve as de facto certifiers of their own extracts; generic root powder at 1000–1500 mg/day has undisclosed bioactive content. Five label red flags: no KSM-66 / Sensoril / branded-extract name on Supplement Facts; "standardized" without named extract identity; universal stress-relief or testosterone-boosting language without population caveat; generic root powder at high-dose serving sizes; no USP / NSF / ConsumerLab seal and no published Certificate of Analysis. Defensible use: 8-week KSM-66 trial at 300–600 mg/day for chronically stressed adults matching the Chandrasekhar population, or for overweight, fatigued men 40–70 matching the Lopresti cohort.
⏱ 5 min read
In This Section
  1. Which Ashwagandha Marketing Claims Have the Weakest Evidence
  2. Why the Retail Ashwagandha Market Fails Label Verification
  3. Five Label Red Flags Specific to Ashwagandha Products
  4. What We'd Still Recommend

Which Ashwagandha Marketing Claims Have the Weakest Evidence

Most ashwagandha marketing rests on a single sentence: it reduces stress and supports testosterone. The published evidence does not support that universal reading — four specific claims are weaker than the marketing implies.

"Cortisol reduction for everyone." Chandrasekhar 2012 enrolled chronically stressed adults (n=64, PSS baseline above 14, KSM-66 300mg twice daily for 60 days) and measured a 27.9% mean cortisol reduction vs 7.9% placebo. The result is real, but the population boundary is the principal finding — applying it to adults with low-normal baseline cortisol is the most common evidence extrapolation in ashwagandha marketing.

HPA-axis and GABAergic mechanism claim without direct receptor-level confirmation. Hypothalamic-pituitary-adrenal (HPA) axis downregulation and GABA-A receptor modulation are biologically plausible. Neither has been confirmed by direct receptor-binding assays or dose-response measurement in adequately powered independent human trials; the mechanism claim is a plausible framing, not a confirmed one.

The emotional-blunting anecdote promoted to RCT-grade certainty. A consistent minority of Week 8+ users describe affective flattening beyond clinical "calm" into a blunted emotional range. The 8-weeks-on / 2-weeks-off cycling convention emerged entirely from community experience — no clinical validation, no measured endpoint, no confirmed mechanism.

"Safe to take long-term." No published ashwagandha trial exceeds 12 weeks of continuous dosing. Long-term hepatotoxicity signal is sparse (case-report literature only); thyroid-axis effects (TSH / T3 / T4 upregulation; ashwagandha is contraindicated in hyperthyroid patients) are documented but not quantified in long-term trials. The defensive "supports long-term use" framing outruns the trial-duration evidence by a wide margin.

Why the Retail Ashwagandha Market Fails Label Verification

The retail ashwagandha market has a standardization gap wider than the average supplement category. Three verification failures recur.

Withanolide-content variability between KSM-66 and Sensoril. KSM-66 (root-only, Ixoreal Biomed) standardizes to ≥5% withanolides; Sensoril (root + leaf, Natreon Inc., including the withaferin-A fraction) sits near 10%. Generic root powder with no named extract sits well below both, often with undisclosed assay on the Certificate of Analysis. A "500 mg ashwagandha" capsule can sit at any point in that range — and the trial dosing decisions were tied to the high end.

"500 mg ashwagandha" labels without withanolide % on the Supplement Facts panel. The mg-per-serving figure tells the consumer nothing about bioactive content. Most retail SKUs place the entry under a generic "Ashwagandha (root)" line with no disclosed percentage.

No retail SKU commissions independent third-party withanolide assays. Ixoreal Biomed (KSM-66) and Natreon Inc. (Sensoril) publish internal standardization targets and serve as the de facto certifiers of their own extracts. Independent USP, NSF, or ConsumerLab assays of retail-SKU withanolide content are rarely published.

Five Label Red Flags Specific to Ashwagandha Products

(a) KSM-66, Sensoril, or any branded-extract name absent from the Supplement Facts panel. Positive clinical evidence rests on KSM-66 (Ixoreal), Sensoril (Natreon), or a small set of independently-funded trials on those extracts. A label that names none of them sells positioning, not a clinical-trial-grade ingredient.

(b) "Standardized" without a named extract identity. "Standardized" without naming KSM-66®, Sensoril®, or an equivalent trade name with documented withanolide targets is positioning vocabulary — the positive evidence does not transfer to unspecified "ashwagandha."

(c) "Natural stress relief" or "boosts testosterone" without a population caveat. Marketing that does not name the population boundary (chronically stressed adults, overweight men 40–70, resistance-trained men) is making a claim the data does not support — the strongest RCT cohorts all had specific baseline characteristics that drove the effect.

(d) Generic root powder sold at "high-dose" 1000–1500 mg/day serving sizes. With undisclosed withanolide content, a 1500 mg/day generic powder delivers an unknown bioactive payload — well below the withanolide exposure in any KSM-66 or Sensoril trial.

(e) No third-party USP / NSF / ConsumerLab seal AND no published Certificate of Analysis. Without independent verification or a public CoA, the consumer is relying on the manufacturer's internal QC for the bioactive content that drives the clinical effect.

What We'd Still Recommend

The honest framing is not "ashwagandha does nothing." For a chronically stressed adult matching the Chandrasekhar 2012 population (PSS > 14) or an overweight, fatigued man 40–70 matching the Lopresti 2019 cohort, an 8-week trial of KSM-66 at 300–600 mg/day is defensible on the published evidence. Outside those populations, the evidence does not support the use.

Choose KSM-66 (root-only, ≥5% withanolides) at 300mg BID or 600mg QD, run an 8-week trial, and pre/post-test salivary cortisol or serum testosterone at week 0 and week 8. For the trial-design detail behind the Chandrasekhar and Lopresti RCTs and the Ixoreal / Natreon funder-capture structure they sit on, see the clinical-evidence article on this page; for the lived-experience detail behind Week 8 emotional-blunting and the cycling convention, see the patient-experience article on this page.

See also: ashwagandha buyer guide — how to read a withanolide % label, distinguish KSM-66 from generic root powder, and avoid the standardization trap before you buy.

Every topic on UnusualRemedies is explored through three lenses: evidence, experience, and uncertainty. Read about our methodology →

You Might Also Investigate
Repurposed Pharmaceuticals / Autoimmune / Pain Management

Low-Dose Naltrexone (LDN)

Naltrexone is FDA-approved at 50mg for opioid and alcohol use disorders. Low-dose naltrexone uses 1.5-4.5mg — one-tenth the dose — for autoimmune disease, fibromyalgia, and multiple sclerosis. Small RCTs show genuine benefit. The mechanism is plausible. The trials will likely never be funded, because naltrexone is generic.
Explore →
Brain Health / Supplements

Magnesium Threonate (Magtein)

A single human RCT with 44 participants is the entire clinical evidence base for a $500 million supplement market — and the patent holder funds most of the research
Explore →
Topical / Detox / Traditional Medicine

Castor Oil Packs

The entire modern castor oil pack protocol traces to Edgar Cayce's 1930s psychic readings — not medical research. The one immunological study (Grady 1993, n=36, no placebo) has never been replicated in 30 years. Queen of Thrones built a $10M+ brand on it. 500 million TikTok views later, the evidence base has not changed.
Explore →